J&J Expands US Rollout of TECNIS PureSee IOL for Cataract Surgery
JNJ sits 62% above its 52-week low of $149.04 on light trading volume (0.1× avg).
Summary
Johnson & Johnson is expanding the U.S. availability of its TECNIS PureSee IOL, an extended depth of focus lens for cataract surgery. This new lens aims to improve visual clarity and quality for patients, with 97% reporting no bothersome visual disturbances. This is a positive product development for J&J's Surgical Vision segment, though the financial impact on the overall company is not detailed.
At the time of this announcement, JNJ was trading at $240.87 on NYSE in the Life Sciences sector, with a market capitalization of approximately $579.8B. The 52-week trading range was $149.04 to $251.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BayStreet.